Literature DB >> 3776843

Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.

D S Weiland, M A Konstam, D N Salem, T T Martin, S R Cohen, M R Zile, D Das.   

Abstract

Although vasodilators improve cardiac output in severe left ventricular (LV) failure, the degree to which reduction in mitral regurgitation (MR) contributes to this response is unknown. In the present study, nitroprusside-induced changes in forward cardiac output were compared with simultaneous radionuclide LV output in 14 patients with severe LV systolic dysfunction in the absence of known primary valvular disease. Regurgitant output was estimated as LV output minus forward output and regurgitant fraction was calculated as regurgitant output/LV output. At rest, LV ejection fraction averaged 0.16 +/- 0.04 (mean +/- standard deviation). Patients were classified into 2 groups based on regurgitant fraction at rest. Group I (n = 5) had little or no detectable valvular regurgitation, with regurgitant fraction less than 0.10; group II (n = 9) had evidence of MR with regurgitant fraction greater than 0.30. Nitroprusside increased forward cardiac output in all patients in both groups, but this effect was significantly greater in group II (64 +/- 34%) than in group I (31 +/- 17%) (p less than 0.01). Nitroprusside decreased regurgitant fraction in all group II patients, with mean regurgitant fraction decreasing from 0.44 +/- 0.12 to 0.26 +/- 0.15 (p less than 0.005). Thus, a large percentage of patients with severe LV systolic dysfunction have clinically relevant MR, defined as a regurgitant fraction greater than 0.30. Nitroprusside has a greater effect on forward cardiac output in patients with LV failure and MR than in patients with comparable ventricular dysfunction in the absence of detectable MR.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3776843     DOI: 10.1016/s0002-9149(86)80036-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Role of vasodilators in regurgitant valve disease.

Authors:  Artur Evangelista; Pilar Tornos; Antonia Sambola; Gaieta Permayer-Miralda
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

Review 2.  Medical treatment of end-stage heart failure.

Authors:  G Binetti; M Senni; F Colombo; G Tasca; F Mamprin; R Caporale; P Ferrazzi; A Gamba; M Glauber; G Troise; R Fiocchi
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

3.  Reduction in mitral regurgitation during therapy guided by measured filling pressures in the ESCAPE trial.

Authors:  Maryse Palardy; Lynne W Stevenson; Gudaye Tasissa; Michele A Hamilton; Robert C Bourge; Thomas G Disalvo; Uri Elkayam; James A Hill; Sharon C Reimold
Journal:  Circ Heart Fail       Date:  2009-04-14       Impact factor: 8.790

4.  Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial.

Authors:  B Seneviratne; G A Moore; P D West
Journal:  Br Heart J       Date:  1994-07

5.  Renin-angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction.

Authors:  Kitae Kim; Shuichiro Kaji; Manabu Kasamoto; Ryosuke Murai; Yasuhiro Sasaki; Takeshi Kitai; Takafumi Yamane; Natsuhiko Ehara; Atsushi Kobori; Makoto Kinoshita; Yutaka Furukawa
Journal:  Open Heart       Date:  2017-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.